About 40% of dogs over the age of 12 will develop a certain level of canine cognitive dysfunction, also known as canine dementia. A pilot clinical study conducted for dogs with CCD has examined the drug Ropesalazine, which is a candidate for the treatment of patients with human Alzheimer's.
According to the manufacturer of the drug, GNT Pharma, based on South Korea, Ropesalazine has shown efficacy in patients with canine dementia, returning to normal cognitive function and daily activity after eight weeks of treatment.
Thumbnail: Photography © CatLane | Getty Images.
About the author
Jackie Brown is a freelance Southern California writer specializing in the pet industry. Reach it on jackiebrownwriter.wordpress.com.
Editor's Note: This article appeared in the Dogster magazine. Have you seen the new Dogster magazine in stores? Or in the waiting room of your vet's office? Sign up now to receive the Dogster magazine directly to you!